With a fresh phase 3 win for Kerendia, Bayer is one step closer to pushing the ascendant drug into a much broader population ...
Data to be presented include two subgroup analyses from the pivotal Phase III FINEARTS-HF trial, which assessed the safety and efficacy of finerenone versus placebo in heart failure (HF) patients with ...
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that data from 13 new analyses from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the American ...
WHIPPANY, N.J.--(BUSINESS WIRE)-- Bayer today announced new Phase III investigational data from the pivotal FINE-ONE trial showing that KERENDIA ® (finerenone) significantly reduced urine ...
Bayer BAYRY announced encouraging detailed results from the late-stage FINEARTS-HF study on finerenone. Finerenone is marketed as Kerendia or Firialta in some countries. The drug is approved for the ...
People with diabetes have a higher risk of many different health issues, including kidney and heart problems. Although various medicines can help reduce the risk of these issues, many people with ...
Bayer filed a patent infringement lawsuit against Macleods Pharmaceuticals on Oct. 20 in Delaware District Court over Macleods' attempt to market a generic version of Kerendia, a medication for ...
Bayer Healthcare Pharmaceuticals and its affiliates filed a patent infringement lawsuit against Dr. Reddy's Laboratories (DRL) on Oct. 24 in New Jersey District Court over DRL's attempts to market a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results